INM news

InMed Pharmaceuticals Inc. has obtained shareholder approval for a corporate name change to Mentari Therapeutics, Inc., and completed a share consolidation 1:10 effective November 5, 2026, with its NASDAQ: INM shares continuing to trade.

InMed Pharmaceuticals reported its first quarter fiscal 2027 financial results and is advancing its proposed merger with Mentari Therapeutics, which is expected to close in Q4 2026. The company will also hold an annual general and special meeting on November 4, 2026, to secure shareholder approval f…

InMed received notice that shareholders' equity fell below $2.5M due to merger expenses. The company expects to regain compliance upon closing the Mentari merger in Q4 2026.

InMed Pharmaceuticals filed an amendment to its previously signed merger agreement with Mentari Therapeutics, Inc. This document confirms the approval of the transaction by the relevant boards of directors for Parent and Merger Subs.

InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after its stock traded at or above that level for 10 consecutive business days. The company had been notified of non-compliance on March 27, 2026, but successfully remedied the listing defici…